Cryosite Limited (CTE) AI Stock Analysis

• Market Cap: AU$53.20M
• Dividend Yield: N/A
• Average Volume (3M): 1.97K
• Price to Earnings (P/E): 10.7
• Beta (1Y): -0.62
• Revenue Growth: 11.93%
• EPS Growth: 2.39%
• Country: AU
• Employees: 25
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 0.02
• Shares Outstanding: 48,809,563
• 10 Day Avg. Volume: 3,337
• 30 Day Avg. Volume: 1,969
• PEG Ratio: 8.08
• Price to Book (P/B): 15.22
• Price to Sales (P/S): 2.58
• P/FCF Ratio: 24.60
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 60 Neutral
• Price Target: AU$1.50 ▲(50.00% Upside)
• Action: Reiterated Date: 02/10/26
• Date: Action: Reiterated 02/10/26

The score is driven mainly by solid financial performance (strong margins and revenue growth) but is held back by weaker cash-flow trends and balance-sheet reliance on debt. Technically, momentum is strong but extremely overbought (very high RSI), increasing near-term risk. Valuation is a drag due to a relatively high P/E and no dividend yield provided.

Positive Factors

High Profitability Margins

Cryosite's high gross (62.98%) and net (13.35%) margins reflect structural pricing power and operational efficiency in temperature‑controlled biorepository services. Sustained margins support reinvestment into facilities and technology, provide a cushion versus volume swings, and improve long‑term resilience of cash generation.

Negative Factors

Declining Free Cash Flow Growth

A 32.88% decline in free cash flow growth signals weakening cash generation momentum. Reduced FCF constrains the company's ability to internally fund capex, expand facilities, or pay down debt, increasing dependence on external financing and limiting strategic flexibility over the medium term.

Cryosite Limited Business Overview & Revenue Model

Company Description

Cryosite Limited offers outsourced clinical trials logistic services in Australia. It operates through two segments, Clinical Trials and Biological Services Logistics, and Cord Blood and Tissues Storage. The Clinical Trials and Biological Services...

Read more

Cryosite Limited offers outsourced clinical trials logistic services in Australia. It operates through two segments, Clinical Trials and Biological Services Logistics, and Cord Blood and Tissues Storage. The Clinical Trials and Biological Services...

How the Company Makes Money

Cryosite Limited generates revenue primarily through its biobanking services, which involve the collection, processing, and storage of umbilical cord blood and tissue from newborns. This service typically comes with an initial fee for collection a...

Read more

Cryosite Limited generates revenue primarily through its biobanking services, which involve the collection, processing, and storage of umbilical cord blood and tissue from newborns. This service typically comes with an initial fee for collection a...

Cryosite Limited Financial Statement Overview

Breakdown	TTM	Jun 2025	Jun 2024	Jun 2023	Jun 2022	Jun 2021
Income Statement
Total Revenue	15.75M	14.12M	12.61M	11.94M	11.76M	10.02M
Gross Profit	9.29M	8.89M	7.99M	6.48M	6.27M	5.31M
EBITDA	3.74M	3.41M	3.04M	2.30M	2.40M	1.65M
Net Income	2.18M	1.88M	1.84M	1.41M	1.36M	652.57K
Balance Sheet
Total Assets	26.55M	19.46M	19.71M	22.65M	21.50M	21.99M
Cash, Cash Equivalents and Short-Term Investments	2.54M	5.06M	4.70M	5.73M	5.34M	3.88M
Total Debt	8.82M	2.27M	2.44M	2.61M	849.76K	1.07M
Total Liabilities	22.94M	17.07M	18.26M	19.86M	19.64M	21.17M
Stockholders Equity	3.61M	2.39M	1.45M	2.78M	1.86M	819.23K
Cash Flow
Free Cash Flow	-1.70M	1.48M	2.44M	1.19M	1.63M	80.07K
Operating Cash Flow	2.23M	2.06M	2.90M	1.49M	2.49M	476.96K
Investing Cash Flow	-3.84M	-420.00K	727.00K	-1.33M	-863.19K	-396.89K
Financing Cash Flow	-332.00K	-1.29M	-3.50M	-768.00K	-148.99K	-260.78K

Cryosite Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Positive
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:CTE, the sentiment is Negative. The current price of 1 is below the 20-day moving average (MA) of 1.16, below the 50-day MA of 1.16, and above the 200-day MA of 0.98, indicating a neutral trend. The MACD of -0.02 indicates Positive momentum. The RSI at 19.48 is Positive, neither overbought nor oversold. The STOCH value of 22.76 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:CTE.

Cryosite Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CTE	60 Neutral	AU$53.20M	10.72	72.82%	―	11.93%	2.39%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
RHY	49 Neutral	AU$64.67M	-4.75	-476.27%	―	―	56.42%
MAP	49 Neutral	AU$42.02M	-1.06	-63.04%	―	29.60%	33.00%
LDX	46 Neutral	AU$168.57M	-7.39	-164.12%	―	12.96%	40.81%
BDX	42 Neutral	AU$33.18M	-2.45	-164.22%	―	―	23.85%
IIQ	38 Underperform	AU$49.98M	-3.02	-37.14%	―	2.33%	12.50%

Cryosite Limited Corporate Events